Navigation Links
FDA Approves New Roche West Nile Virus Blood Screening Test
Date:9/3/2007

multiplex HIV, HCV, and HBV test is currently under FDA review.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005 sales by the Pharmaceuticals Division totaled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our website http://www.roche.com.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Melinda Baker

Molecular Diagnostics Communications

Phone: 925-730-8379


'/>"/>
SOURCE Roche Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA approves new device to treat womens bleeding disorder
3. FDA Approves New HIV Drug, Viread
4. FDA Approves Birth Control Skin Patch
5. FDA approves surgical gel
6. FDA Approves New Arthritis Drug, Bextra
7. FDA Approves Elidel Cream for Eczema
8. FDA approves drug for rare liver disease
9. FDA approves first pocket-sized EKG machine
10. FDA Approves New Anti-Clotting Drug
11. FDA Approves New surgery Treatment for Farsightedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... for people to comfortably hold a tablet while reducing the likelihood of it dropping. ...
(Date:9/2/2015)... ... September 02, 2015 , ... Available ... marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , an evolution ... biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing and moisturizing. ...
(Date:9/2/2015)... ... , ... The payroll conference theme this year is "TAKING ... legislative updates, including unemployment, global payroll best practices, and the latest trends in ... the American Payroll Association, Barnett Associates, and the IRS, will keep payroll professionals ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in 2007 ... and education, and helping fund more research remains our top priority,” commented Christine ...
(Date:9/2/2015)... ... ... Pentec Health, Inc., a national leader in outsourced pharmacy services, has been ... Less than 5 % of this year’s 5000 honorees share the “six-time” recognition; Pentec ... revenue growth rate of 65% sustained its most recent achievement. As an Inc. 5000 ...
Breaking Medicine News(10 mins):Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... UPMC Health Plan announced the,launch of a small ... small businesses -- UPMC Health Plan,s Small Business ... with 2 to 99,employees a high- quality, easy-to-implement ... tools, and a,dedicated account manager and customer service ...
... shows no link , THURSDAY, Oct. 18 (HealthDay News) -- ... or after exercise will not prevent muscle soreness, a new ... each involving from 10 to 30 people. , Nine of ... and the time spent stretching by participants varied from 40 ...
... and,Reported Diluted Earnings per Share Decreased 1% to $0.84. Diluted Earnings ... 2007 First Nine Months Worldwide Net Revenue Increased 10% to $16.6, ... Share, Before Certain Significant Items, Increased 10% ... to ...
... MITI ), a biopharmaceutical company focusing on ... treatment of cancer,inflammatory and autoimmune diseases, announced today ... Product Dossier (IMPD),for the conduct of a phase ... lymphoblastic leukemia (ALL) in Germany. MT103, a BiTE(R) ...
... 2,200-plus healthcare professionals and exhibitors registered for the,first-ever ... CHICAGO, Oct. 17 With studies from ... of students and,adults enrolling in distance education in ... Information and Management Systems Society (HIMSS),will host its ...
... Our ... Telemedicine Product Line, SUN VALLEY, Calif., Oct. 18 ... new,Bluetooth(R) enabled telemedicine products to their line of disease,management solutions for ... "The addition of A & D,s Bluetooth(R) enabled Blood Pressure ...
Cached Medicine News:Health News:UPMC Health Plan Launches New Product for Small Businesses 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 2Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 3Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 4Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 5Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 6Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 7Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 8Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 9Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 10Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 11Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 12Health News:Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months 13Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Health News:Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 2Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 3Health News:HIMSS' Second Virtual Conference & Expo Less Than a Month Away 4Health News:XTend Medical (XDMC) Adds New Bluetooth(R) Telemedicine Products From A&D Medical 2
(Date:9/1/2015)... Mass. , Sept. 1, 2015  Shareholder rights ... whether certain officers and directors of ConforMIS, Inc. (NASDAQGS: ... ConforMIS is a medical technology company that uses its ... joint replacement implants that are individually sized and shaped ... this press release on the law firm,s Shareholder Rights ...
(Date:9/1/2015)... Sept. 1, 2015  Amgen (NASDAQ: AMGN ... in the areas of Alzheimer,s disease and migraine. ... disease by teaming up with Novartis on a ... at genetically predisposed individuals at risk of developing ... on the commercialization of its migraine programs in ...
(Date:9/1/2015)... 2015  AccuTec Blades, Inc. today announced the acquisition ...  EPC announced in May 2015 its intent to discontinue ... and Obregon, Mexico . ... Rick Gagliano , the newly-appointed ... "Our new name, AccuTec Blades, reflects the precision and ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2
... (Nasdaq:,EXEL) today presented data from its phase 2 ... to diabetic nephropathy. XL784 is a small,molecule inhibitor ... a role in the pathogenesis of diabetic nephropathy ... poster session (Abstract/Poster PO1030) at,the American Society of ...
... IDM-2101 showed an improvement in median survival vs. ... parallel external controls -, ... ) today announced updated results from the Phase 2 study of,its ... specific cytotoxic T lymphocyte (CTL) responses,and showed a positive survival trend ...
Cached Medicine Technology:Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 2IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 3IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: